NIH Funding Opportunities

Subscribe to NIH Funding Opportunities feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 12 min ago

Notice of Correction to RFA-RM-19-008 NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)

Tue, 07/30/2019 - 10:26
Notice NOT-RM-19-013 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Revised NIAID Policy for T32 and T35 Competing Renewal Application Submissions

Tue, 07/30/2019 - 10:21
Notice NOT-AI-19-064 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Tue, 07/30/2019 - 00:10
Funding Opportunity PAR-19-325 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Categories: Science RSS Feeds

NOTICE OF INFORMATION: NIGMS Priorities for Sepsis Research

Mon, 07/29/2019 - 11:51
Notice NOT-GM-19-054 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Request for Information (RFI): Precision Nutrition Tools for Continuous Monitoring of Nutrients and Metabolites in Humans

Mon, 07/29/2019 - 09:50
Notice NOT-DK-19-021 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)

Mon, 07/29/2019 - 01:25
Funding Opportunity PAR-19-319 from the NIH Guide for Grants and Contracts. The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.
Categories: Science RSS Feeds

Notice of Change to RFA-AG-20-022 "Aging, Driving and Early Detection of Dementia (R01 Clinical Trial Optional)"

Mon, 07/29/2019 - 01:08
Notice NOT-AG-19-032 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Polycystic Kidney Disease Research and Translation Core Centers (U54 Clinical Trial Not Allowed)

Fri, 07/26/2019 - 11:21
Funding Opportunity RFA-DK-19-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications for Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The RTCCs are expected to work collaboratively with the Central Coordinating Site (CCS) as part of a PKD Research Consortium and serve as a national resource for the larger research community. The RTCCs should develop and share research resources (e.g. reagents, tools etc.), services and expertise that would be difficult or impractical to support in individual labs. The FOA is open to new applications, not renewals. Previously funded PKD Centers may apply as new centers.
Categories: Science RSS Feeds

Central Coordinating Site for the Polycystic Kidney Disease Research and Translation Core Centers (U24 Clinical Trial Not Allowed)

Fri, 07/26/2019 - 11:21
Funding Opportunity RFA-DK-19-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The CCS is expected to work collaboratively with four RTCCs as part of the PKD Research Consortium and serve as a national resource for the larger research community. The CCS will provide central administrative and communications support for the Consortium. All activities within the Consortium are expected to address the overall goal of improving our understanding of the pathogenesis, progression, prevention and clinical management of PKD through enhanced sharing of resources and establishment of a robust research community. This FOA is a companion announcement to RFA-DK-19-010:Polycystic Kidney Disease Research and Translation Core Centers (U54).
Categories: Science RSS Feeds

Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research

Fri, 07/26/2019 - 07:30
Notice NOT-OD-19-128 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Consolidated Notice on NIMH Clinical Trials Policies

Thu, 07/25/2019 - 10:16
Notice NOT-MH-19-031 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional)

Thu, 07/25/2019 - 09:21
Funding Opportunity PAR-19-318 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.
Categories: Science RSS Feeds

Notice of System Change and Procedure for Requesting an Extension to Early Stage Investigator (ESI) Status

Thu, 07/25/2019 - 08:57
Notice NOT-OD-19-125 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Notice of Clarification of Eligibility for PAR-19-286 "Postdoctoral Research Associate Training (PRAT) Program (Fi2)

Thu, 07/25/2019 - 07:46
Notice NOT-GM-19-052 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Pages